Skip to Main Content

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

Conditions

Diseases of the Kidney & Urinary Tract

Phase IIB

What is the purpose of this trial?

Detailed Description:

Safety and efficacy of 50mg tesevatinib in comparison to placebo in patients with autosomal dominant polycystic kidney disease (ADPKD) will be assessed.

The primary purpose of this study is focused on evaluating the change from baseline in height-adjusted total kidney volume (htTKV) as measured by magnetic resonance imaging (MRI) at Months 12, 18, and 24 in patients with ADPKD treated with tesevatinib or placebo.

If eligible for the study participation, subjects will be randomly assigned to either investigational treatment group or placebo group. Treatment group will receive 50mg tesevatinib once daily for 24 months and control group will receive the placebo once daily for 24 months.

  • Trial with
    Kadmon Corporation, LLC
  • Start Date
    02/26/2018
  • End Date
    06/29/2020
Trial Image

For more information about this study, contact:

Yasemin Kavak

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

  • Last Updated
    08/20/2018
  • Study HIC
    #2000021472